This is an observational, multicenter, prospective study on patients with severe eosinophilic asthma treated with benralizumab aimed at evaluating the achievement of partial and complete clinical remission.
Adults (≥ 18 years old) diagnosed with severe uncontrolled eosinophilic asthma.
Benralizumab has been prescribed according to the approved label and local reimbursement criteria
Provision of signed Informed Consent Form (ICF) prior to any study-related activities
Benralizumab has been initiated within 7 days prior to study enrollment or is planned to be initiated within 7 days after enrollment (in the latter case, provided that the decision to prescribe benralizumab is made prior to the decision to enroll the patient in the study).
Benralizumab treatment within the 12 months prior to study enrollment and up to 8 days before enrollment
Previous participation (in the 12 months before enrollment), current participation or plan to participate within the follow up period to any other clinical trial.
Contraindication to benralizumab as per current Summary of Product Characteristics (SmPC).
Pregnant or lactating women.